Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in treatment-naive CLL/SLL (Japanese)
NCT02556892Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Janssen Pharmaceutical. Primary endpoints: Intensity of Adverse Events and Incidence of Adverse Events. Started Jul 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02556892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556892.